Antibody-drug conjugate combined with PD-1 inhibitor

This page covers all Antibody-drug conjugate combined with PD-1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 (disitamab vedotin); PD-1 (tislelizumab).

Targets

HER2 (disitamab vedotin); PD-1 (tislelizumab)

Marketed (1)

• Disitamab Vedotin combined with Tislelizumab · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Oncology
  Disitamab vedotin delivers a cytotoxic payload to HER2-expressing cancer cells while tislelizumab simultaneously blocks PD-1 to enhance anti-tumor immune response.

Patent intelligence

• antibody drug conjugate combined with pd 1 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates